Sriya Gunawardena - Sanofi | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 39 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Caplacizumab Improves Clinical Outcomes and is Well Tolerated Across Clinically Relevant Subgroups of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Katerina Pavenski,Marie Scully,Paul Coppo,Spero Cataland,Paul Knoebl,Flora Peyvandi,Johanna A. Kremer Hovinga,Javier de la Rubia,Umer Khan,Ana Paula Marques,Sriya Gunawardena

Research and Practice in Thrombosis and Haemostasisno. 5 (2024): 102512-102512

引用0浏览0WOS引用

Efanesoctocog Alfa Treatment Outcomes in Subjects ≥50 Years of Age from the Xtend-1 Trial

Johannes Oldenburg,Barbara Konkle,Toshko Lissitchkov,Pratima Chowdary,Liane Khoo,Olga Katsarou,Katsuyuki Fukutake,Annette von Drygalski,Elena Santagostino, Helena Palmborg,Linda Bystricka,Jennifer Dumont,Alejandro Fernandez,Sriya Gunawardena

HAEMOPHILIA (2024): 93-94

引用0浏览0引用

Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A

NEW ENGLAND JOURNAL OF MEDICINEno. 3 (2024): 235-246

引用0浏览0WOS引用

Complex Immunogenicity Assessment in Caplacizumab-Treated Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura Who Have Received Plasma Exchange

Brendy Van Butsel, Maria Laura Sargentini-Maier,Ana Paula Marques, Yana Vandenbossche, Gabriela Marcheva,Sriya Gunawardena, Samuel Pine

Research and practice in thrombosis and haemostasisno. 8 (2024): 102620-102620

引用0浏览0WOS引用

PB0312 Assessment of Post-Treatment Anti-Drug Antibodies to Caplacizumab in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

B. Van Butsel, M. Sargentini-Maier, A. Marques, H. Okada,S. Gunawardena, S. Pine

Research and Practice in Thrombosis and Haemostasis（2023）

引用0浏览0引用

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children with Severe Hemophilia A in the XTEND-Kids Phase 3 Study

Lynn Malec,Amy Dunn,Manuel Carcao,Bulent Zulfikar,Ruben Berrueco,Simon Brown,Umer Khan,Sriya Gunawardena, Graham Neill,Lydia Abad-Franch,Linda Bystricka,Elena Santagostino,Sophie Susen

Bloodno. Supplement 1 (2023): 3993-3993

引用0浏览0引用

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

Flora Peyvandi,Cristina Tarango,Mindy Simpson,Manuela Albisetti,Maria Teresa Alvarez-Roman,Anthony K. C. Chan,Julie Curtin,Linda Bystricka,Elena Santagostino,Ekaterina Gresko,Sriya Gunawardena,Chandravathi Vage,Nancy Wong

Bloodno. Supplement 1 (2023): 506-506

引用0浏览0引用

LB 01.1 Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age with Severe Hemophilia A

L. Malec,F. Peyvandi, A. Chan,C. Koenigs, B. Zulfikar, H. Yuan, M. Simpson,M. Alvarez-Román,M. Carcao,J. Staber, A. Dunn, S. Chou,R. D’Oiron,M. Albisetti, M. Demissie,E. Santagostino, A. Yarramaneni,L. Abad-Franch,S. Gunawardena, K. Fijnvandraat

Research and Practice in Thrombosis and Haemostasis (2023)

引用0浏览0引用

A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAPLACIZUMAB WITHOUT FIRST-LINE THERAPEUTIC PLASMA EXCHANGE IN ADULTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA

S. Gunawardena, A. Hu,L. A. Menapace, H. Okada, B. Accomanda,J. Lin,P. Knoebl

Blood（2022）

引用0浏览0引用

Long‐term Follow‐up of Patients Treated with Caplacizumab and Safety and Efficacy of Repeat Caplacizumab Use: Post‐HERCULES Study

Marie Scully,Javier de la Rubia,Katerina Pavenski,Ara Metjian,Paul Knoebl,Flora Peyvandi,Spero Cataland,Paul Coppo,Johanna A. Kremer Hovinga,Jessica Minkue Mi Edou,Rui De Passos Sousa,Filip Callewaert,Sriya Gunawardena,Julie Lin

Journal of Thrombosis and Haemostasis（2022）

引用6浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn